# Reliant Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/reliant-pharmaceuticals

- Industry: Pharmaceuticals
- Headquarters: US
- Website: www.reliantrx.com
- Total disclosed funding: $150M
- Latest round: Series C (Jun 1, 2001)
- Investors on record: 2

## About

Based in New Jersey, US, and founded in 1999 by Stefan Aigner, Reliant Pharmaceuticals engages in the development, commercialization, and marketing of prescription cardiovascular therapeutic products. In December 2003, Reliant Pharmaceuticals raised USD 137 million in Series D financing from Goldman Sachs. In November 2007, Reliant Pharmaceuticals was acquired by GlaxoSmithKline for GBP 800 million. As of October 2005, the company's CEO is Ernest Mario.
 
Reliant has developed a portfolio of specialty medicines combating heart diseases, such as InnoPran XL for hypertension, AXID for gastroesophageal reflux disorder, DynaCirc CR for hypertension, Lescol XL for cholesterol management, and Rythmol SR for atrial fibrillation, including US rights to Lovaza (TM) (omega-3-acid ethyl esters), a treatment for adult patients with very high levels of triglycerides. Triglycerides are fatty substances in the blood associated with increased risks of coronary artery disease. Lovaza is indicated as an adjunct to a diet to reduce triglyceride levels in adults.

## Funding rounds

- Series C, Jun 1, 2001, $150M — Bay City Capital, Alkermes plc

## Investors

- Bay City Capital (https://capitalatlas.ai/funds/bay-city-capital) — Series C
- Alkermes plc — Series C